Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05846009 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT05846009 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 76 participants.
The verdict
NCT05846009, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of the first-in-human (FIH) study is to obtain safety, tolerability, and pharmacokinetic information on SAR442501 in a healthy adult volunteer population using an integrated single ascending dose (SAD)-multiple ascending dose (MAD) parallel cohort study design.
Interventions
- DRUG Placebo
- DRUG SAR442501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2020-11-18 |
| Est. Completion | 2022-01-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05846009
The ClinicalTrials.gov registry entry for NCT05846009 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05846009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05846009 about?
NCT05846009 is a clinical study titled "A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects". The purpose of the first-in-human (FIH) study is to obtain safety, tolerability, and pharmacokinetic information on SAR442501 in a healthy adult volunteer population using an integrated single ascending dose (SAD)-multiple ascending dose (MAD) parallel cohort study design.
What is the current status of trial NCT05846009?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2020-11-18. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT05846009?
The interventions under investigation include: Placebo (DRUG), SAR442501 (DRUG).
Who is sponsoring clinical trial NCT05846009?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.